Written by Ad OpsHistory and Cultural Impact
Charlotte's Web (CBD) rose to prominence in the early 2010s after being bred in Colorado by the Stanley Brothers with a singular goal: maximize cannabidiol (CBD) while minimizing delta-9 THC to near trace levels. The cultivar is named for Charlotte Figi, a child with Dravet syndrome whose seizure frequency reportedly dropped dramatically after beginning a CBD-rich cannabis extract derived from this plant. Her story, broadcast widely in 2013 by national media and medical journalists, catalyzed a new era of interest in CBD as a non-intoxicating cannabinoid. Public awareness and policy discourse shifted rapidly, with many states amending laws to allow CBD-rich products for pediatric epilepsy.
The cultivar’s emergence predates the United States’ 2018 Farm Bill that legally defined hemp as cannabis with ≤0.3% delta-9 THC by dry weight. Charlotte's Web fit naturally into this paradigm because it had already been selected for very low THC in the flower, often paired with double-digit CBD. Leafly has long recognized Charlotte’s Web as a CBD-dominant example, frequently cited alongside other low-THC chemotypes such as Remedy. This positioning helped standardize consumer understanding of cannabis chemotypes as THC-dominant, CBD-dominant, or balanced, a framework echoed in scientific and industry references.
Culturally, Charlotte’s Web did more than introduce a cultivar; it reframed the cannabis conversation around wellness, pediatrics, and non-intoxicating phytochemistry. The story accelerated investment into CBD research, spurred the growth of hemp agriculture, and ignited interest in whole-plant compositions rather than isolated compounds. By the mid-2010s, CBD-labeled products proliferated across North America and beyond, and Charlotte’s Web became a shorthand for high-CBD, low-THC cannabis. The cultivar and its namesake remain emblematic of the shift from purely recreational narratives to nuanced, science-forward discussions of cannabinoids.
Genetic Lineage and Breeding
The exact pedigree of Charlotte’s Web (CBD) has been kept proprietary, a common practice among breeders protecting foundational intellectual property. What is well established, however, is its chemotype: CBD-dominant (often called Type III), generally producing far more CBD than THC. In chemotype terms, CBD-dominant plants typically express CBD:THC ratios greater than 20:1, and Charlotte’s Web commonly exceeds that threshold under compliant cultivation. This extreme ratio reflects targeted selection for the CBD synthase pathway and suppression of THC synthase expression.
Breeding for CBD-dominance relies on tracking both cannabinoid gene expression and the plant’s chemical fingerprint over multiple generations. Producers select phenotypes that consistently test with high CBD and very low THC across environments, an essential requirement for regulatory compliance. Since any drift toward THC can push a crop above the legal threshold, breeders focus on stability through clonal propagation and carefully controlled pollination. This genetic stewardship is why Charlotte’s Web became a blueprint for consistent CBD-rich floral biomass in both medical and hemp markets.
In the broader landscape, Charlotte’s Web aligns with a family of CBD cultivars developed around the same period, including lines like ACDC, Cannatonic, and later CBD-dominant offerings bred specifically to remain functionally non-intoxicating. Industry analyses often note that CBD-dominant strains were historically rarer than THC-dominant ones, reflecting decades of illicit-market selection for potent psychoactivity. As legalization expanded, the demand for CBD chemotypes surged, and Charlotte’s Web stood out for its early, well-documented success and recognizable identity. Its lineage remains a guarded asset, but its chemotype is now a cornerstone of modern CBD breeding programs.
Appearance and Bud Structure
Charlotte’s Web typically grows with a sativa-leaning morphology: taller stature, elongated colas, and a relatively open canopy that encourages airflow. In dried flower form, buds are medium to large, often with a tapered, spear-like shape rather than dense, golf-ball nugs. Calyxes can appear slightly elongated, with a medium-green hue interlaced by amber to orange pistils. Trichome coverage is substantial, but the resin tends to be less intensely sticky than high-THC cultivars bred for maximum psychoactive resin.
Under proper cultivation, the flower structure appears well-formed but not overly compact, reflecting a balance between resin production and regulatory compliance goals. Sugar leaves are modest and typically trimmed close to highlight the calyxes for retail or extraction. Expect a frost-speckled surface under good lighting, with a crystalline sheen that belies its low THC status. Overall, the visual appeal is clean, natural, and consistent with modern hemp-style CBD flowers selected for quality extraction and whole-flower use.
Aroma
The aroma of Charlotte’s Web often lands in the herbal-to-woodsy range, with prominent notes suggestive of pine, fresh-cut herbs, and a subtle peppery spice. Many batches display a gentle earthiness anchored by myrcene-like tones, balanced with a minty or coniferous lift that implies pinene. On the finish, a soft clove or black pepper sensation—typical of beta-caryophyllene—can emerge, lending a culinary warmth.
Consumers frequently describe Charlotte’s Web as clean and understated rather than loud or candy-sweet. Some phenotypes add faint citrus top notes, possibly from limonene, which brighten the profile without overwhelming the base. Compared to terpinolene-forward strains that shout with fruit and fuel, Charlotte’s Web has a quieter, more grounded bouquet. This measured aromatic character dovetails with its calm, non-intoxicating composure.
Flavor
The flavor follows the nose: herbal and pine-forward with a dry, peppered mid-palate and a mellow earthy base. On inhalation, expect a crisp, green-herb opening that can feel cool and refreshing, especially in vaporized flower. On exhalation, black pepper and soft clove hints often appear, consistent with beta-caryophyllene’s culinary signature.
Some cuts present a light citrus zest that adds lift to the herbal core. As with the aroma, the flavor is not aggressively sweet; instead it is balanced and naturalistic. The overall impression is clean and soothing, with a lingering woody-herbal echo.
Cannabinoid Profile and Potency
Charlotte’s Web is unequivocally a CBD-dominant cultivar. In flower, CBD content commonly lands in the low- to mid-teens by dry weight, though ranges can vary with phenotype and growing conditions. Many compliant crops are selected to maintain delta-9 THC at or below 0.3% by dry weight, aligning with U.S. hemp regulations. This typically yields CBD:THC ratios of 20:1 or higher, and in some cases 30:1+.
A useful benchmark comes from seed and industry references: historically, any cannabis cultivar producing 4% or more CBD in dry buds has been considered “CBD-rich.” By that standard, Charlotte’s Web substantially exceeds the CBD-rich threshold, often delivering two to four times that minimum or more. Consumers should note that lab reports sometimes list “total THC” (delta-9 THC plus THCA) for compliance, and that number must also remain at or below 0.3% in hemp jurisdictions. As always, check the product certificate of analysis (COA) to see exact cannabinoid percentages.
Minor cannabinoids can be present in small but meaningful amounts. CBG and CBC are occasionally detected and may contribute to perceived effects via the entourage phenomenon. While absolute values vary, full-spectrum products derived from Charlotte’s Web often emphasize a cannabinoid ensemble rather than CBD isolate, reflecting a demand for whole-plant compositions. This approach aligns with consumer interest in multicomponent phytochemistry beyond just headline CBD potency.
Terpene Profile and Aromachemistry
Terpenes shape both aroma and subjective experience, and Charlotte’s Web tends to express a grounded, functional profile. Consumer and producer reports commonly point to myrcene, beta-caryophyllene, and pinene as recurrent players. Myrcene is associated with earthy, herbal notes; beta-caryophyllene conveys pepper and clove; and pinene contributes a distinct pine-like freshness. Secondary terpenes like humulene and limonene may round out the bouquet with woody and citrus elements, respectively.
Leafly emphasizes that terpenes not only drive a strain’s flavor and aroma, they may also modify its effects. In CBD-dominant cultivars like Charlotte’s Web, this can translate to nuanced differences in calm, clarity, or perceived relaxation despite minimal THC. For instance, beta-caryophyllene interacts with CB2 receptors, raising interest in its potential anti-inflammatory role, while pinene is often described as alerting or focus-friendly. Such interactions are not formally standardized, but they align with the reported clear-headed, steady feel of Charlotte’s Web.
Total terpene content in cannabis flower often falls in the 1–4% by weight range in well-cured buds, though hemp-type CBD flowers can present from the sub-1% up to that common cannabis range depending on cultivar and cultivation. Within that total fraction, myrcene can comprise a significant share in many samples, with caryophyllene and pinene frequently following. Exact distributions vary by phenotype, environment, curing, and harvest timing. Because real-world variability is common, consumers should look to batch-specific COAs to see the dominant terpene trio for any given lot.
Experiential Effects and Consumer Reports
As a CBD-dominant cultivar with low THC, Charlotte’s Web is functionally non-intoxicating for most consumers. Typical reports highlight a calm, relaxed baseline with clear thinking and minimal cognitive impairment. Many find it well suited for daytime use, including tasks that require focus, because it lacks the pronounced euphoria or short-term memory disruption associated with high-THC cannabis. The experience is often described as steadying rather than stimulating or sedating.
Some batches and individual sensitivities can produce a mildly noticeable body-lightness or mood lift. This is consistent with reports that elevated CBD can reduce stress perception without driving a classic “high.” Leafly has reported that CBD-dominant cultivars are favored by those who need to medicate throughout the day to manage pain, inflammation, or anxiety while staying functional. Additionally, some users describe deep relaxation and a gentle, mild high with elevated CBD strains classified as sativa by producers, though Charlotte’s Web itself remains chiefly non-intoxicating.
Dose and route matter. Vaporized or smoked flower delivers cannabinoids rapidly, while tinctures and capsules taken orally have slower onsets but longer duration. Because CBD has a wide therapeutic window, many consumers titrate gradually to find a personal “sweet spot,” especially for stress or body comfort. As always, individual responses are heterogeneous, and effects can depend on both chemistry and context.
Potential Medical Uses and Evidence Landscape
CBD has been studied across multiple domains, and Charlotte’s Web is emblematic of CBD-dominant cannabis used for wellness. Robust randomized controlled trials support purified CBD (Epidiolex) for seizure reduction in Dravet syndrome and Lennox–Gastaut syndrome, with labeled maintenance doses commonly 10–20 mg/kg/day. While this clinical data refers to pharmaceutical CBD, it legitimized CBD’s antiseizure potential and accelerated broader research. Many families initially turned to high-CBD, low-THC extracts—like those derived from Charlotte’s Web—when conventional treatments were insufficient, contributing to the cultivar’s renown.
Beyond epilepsy, early studies and reviews suggest CBD may have benefits for anxiety, inflammation, pain, psychosis, and spasms. Leafly’s expert roundups have summarized this literature, noting positive signals on these endpoints while also emphasizing the need for standardized dosing and high-quality trials. For anxiety, human studies have shown CBD’s anxiolytic effects in specific models, with a bell-shaped dose-response reported in some experiments. For pain, data are mixed and condition-specific, with some neuropathic pain and inflammatory pain models showing promise.
Importantly, whole-plant chemovars like Charlotte’s Web deliver CBD alongside minor cannabinoids and terpenes, raising the prospect of entourage or ensemble effects. While the hypothesis that multi-compound profiles can be more effective than isolates remains under active investigation, many patients and clinicians prefer full-spectrum approaches for perceived breadth of action. Observational data and patient-reported outcomes frequently note improvements in sleep quality, stress resilience, and muscle tension with CBD-dominant products. However, these reports should be interpreted as preliminary and individualized rather than definitive medical evidence.
Patients should consult clinicians when integrating CBD into treatment plans, especially if taking medications metabolized by CYP450 enzymes. Quality control is critical: third-party lab testing for potency and contaminants is essential to ensure accurate dosing and safety. As with any supplement or botanical therapy, start-low, go-slow approaches are prudent, and product selection should be guided by verified COAs. Charlotte’s Web’s longstanding presence and consistent CBD-forward profile make it a common reference point in clinical discussions about CBD use.
Comprehensive Cultivation, Compliance, and Quality Considerations
Before discussing cultivation considerations, it’s essential to note that cannabis laws vary by jurisdiction. Always confirm local regulations and licensing requirements, especially regarding hemp’s legal definition and the 0.3% total THC or delta-9 THC thresholds used for compliance. In many regions, crops that exceed the legal THC limit (“go hot”) must be remediated or destroyed, underscoring the importance of compliant genetics and regular testing. For prospective growers, working with licensed programs and vetted clones is an important foundation for success and legality.
Charlotte’s Web expresses a CBD-dominant chemotype aligned with Type III plants, which are typically chosen to maintain very low THC expression through the flowering cycle. Clonal propagation helps preserve this chemotype and reduces the risk of variability that can occur with seed-grown populations. Phenotype drift, environmental stress, and unintended pollination can nudge cannabinoid ratios in undesirable directions, so stable mother stock and clean cultivation practices are central. Many producers test early and periodically to track cannabinoid development and harvest at an appropriate window for compliance and quality.
From an agronomic standpoint, Charlotte’s Web often grows with a sativa-like structure that benefits from thoughtful canopy management. Prudent spacing, airflow, and structural support can help mitigate disease pressure while encouraging uniform flower development. Integrated pest management (IPM) should prioritize prevention: sanitation, scouting, and biological controls suited to your region and legal framework. Because CBD-dominant cultivars are often destined for full-spectrum extraction, cleanliness and contaminant-free production are critical for downstream processing.
In regulated hemp programs, testing typically quantifies THC as either delta-9 THC only or “total THC,” which includes THCA through a conversion factor. This distinction matters operationally because THCA increases during maturation, and “total THC” rules are stricter than delta-9-only thresholds. Many growers time harvests to remain within legal limits while still capturing robust CBD content. Batch-by-batch COAs, verified by accredited laboratories, are a best practice for both farm-gate compliance and market transparency.
Post-harvest handlin
